ID MMP3_HUMAN Reviewed; 477 AA. AC P08254; B2R8B8; Q3B7S0; Q6GRF8; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1991, sequence version 2. DT 04-NOV-2026, entry version 249. DE RecName: Full=Stromelysin-1; DE Short=SL-1; DE EC=3.4.24.17 {ECO:0000269|PubMed:1371271, ECO:0000269|PubMed:21330369}; DE AltName: Full=Matrix metalloproteinase-3; DE Short=MMP-3; DE AltName: Full=Transin-1; DE Flags: Precursor; GN Name=MMP3; Synonyms=STMY1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 18-24. RX PubMed=3360803; DOI=10.1016/s0021-9258(18)68705-8; RA Saus J., Quinones S., Otani Y., Nagase H., Harris E.D. Jr., Kurkinen M.; RT "The complete primary structure of human matrix metalloproteinase-3. RT Identity with stromelysin."; RL J. Biol. Chem. 263:6742-6745(1988). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Fibroblast; RX PubMed=3030290; DOI=10.1042/bj2400913; RA Whitham S.E., Murphy G., Angel P., Rahmsdorf H.J., Smith B., Lyons A., RA Harris T.J.R., Reynolds J.J., Herrlich P., Docherty A.J.P.; RT "Comparison of human stromelysin and collagenase by cloning and sequence RT analysis."; RL Biochem. J. 240:913-916(1986). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=3477804; DOI=10.1073/pnas.84.19.6725; RA Wilhelm S.M., Collier I.E., Kronberger A., Eisen A.Z., Marmer B.L., RA Grant G.A., Bauer E.A., Goldberg G.I.; RT "Human skin fibroblast stromelysin: structure, glycosylation, substrate RT specificity, and differential expression in normal and tumorigenic cells."; RL Proc. Natl. Acad. Sci. U.S.A. 84:6725-6729(1987). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Lin D., Duncan M., Allen E., Araujo R., Aparicio A., Chai A., Chung E., RA Davis K., Federspiel N., Hyman R., Kalman S., Komp C., Kurdi O., RA Lashkari D., Lew H., Namath A., Oefner P., Roberts D., Heller R., RA Davis R.W.; RT "Three matrix metalloproteinases on 81kb of P1 insert."; RL Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Synovium; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLU-45. RC TISSUE=Synovium; RA Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y., RA Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-45. RG SeattleSNPs variation discovery resource; RL Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLU-45. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP ZYMOGEN ACTIVATION, AND FUNCTION. RX PubMed=2383557; DOI=10.1021/bi00476a020; RA Nagase H., Enghild J.J., Suzuki K., Salvesen G.; RT "Stepwise activation mechanisms of the precursor of matrix RT metalloproteinase 3 (stromelysin) by proteinases and (4- RT aminophenyl)mercuric acetate."; RL Biochemistry 29:5783-5789(1990). RN [11] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=1371271; DOI=10.1016/s0021-9258(19)50563-4; RA Ogata Y., Enghild J.J., Nagase H.; RT "Matrix metalloproteinase 3 (stromelysin) activates the precursor for the RT human matrix metalloproteinase 9."; RL J. Biol. Chem. 267:3581-3584(1992). RN [12] RP INVOLVEMENT IN CHDS6. RX PubMed=8662692; DOI=10.1074/jbc.271.22.13055; RA Ye S., Eriksson P., Hamsten A., Kurkinen M., Humphries S.E., Henney A.M.; RT "Progression of coronary atherosclerosis is associated with a common RT genetic variant of the human stromelysin-1 promoter which results in RT reduced gene expression."; RL J. Biol. Chem. 271:13055-13060(1996). RN [13] RP FUNCTION. RX PubMed=11029580; DOI=10.1046/j.1432-1327.2000.01732.x; RA Arza B., Hoylaerts M.F., Felez J., Collen D., Lijnen H.R.; RT "Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue- RT type plasminogen activator."; RL Eur. J. Biochem. 267:6378-6384(2000). RN [14] RP INVOLVEMENT IN CHDS6. RX PubMed=12477941; DOI=10.1056/nejmoa021445; RA Yamada Y., Izawa H., Ichihara S., Takatsu F., Ishihara H., Hirayama H., RA Sone T., Tanaka M., Yokota M.; RT "Prediction of the risk of myocardial infarction from polymorphisms in RT candidate genes."; RL N. Engl. J. Med. 347:1916-1923(2002). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND CATALYTIC ACTIVITY. RX PubMed=21330369; DOI=10.1074/jbc.m111.222430; RA Choi D.H., Kim Y.J., Kim Y.G., Joh T.H., Beal M.F., Kim Y.S.; RT "Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in RT dopaminergic cell death."; RL J. Biol. Chem. 286:14168-14177(2011). RN [16] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=22265821; DOI=10.1016/j.neuint.2012.01.001; RA Shin E.J., Kim E.M., Lee J.A., Rhim H., Hwang O.; RT "Matrix metalloproteinase-3 is activated by HtrA2/Omi in dopaminergic RT cells: relevance to Parkinson's disease."; RL Neurochem. Int. 60:249-256(2012). RN [17] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=35940311; DOI=10.1016/j.antiviral.2022.105388; RA Feng T., Tong H., Ming Z., Deng L., Liu J., Wu J., Chen Z., Yan Y., Dai J.; RT "Matrix metalloproteinase 3 restricts viral infection by enhancing host RT antiviral immunity."; RL Antiviral Res. 0:0-0(2022). RN [18] RP STRUCTURE BY NMR OF CATALYTIC DOMAIN. RX PubMed=7656014; DOI=10.1038/nsb0294-111; RA Gooley P.R., O'Connell J.F., Marcy A.I., Cuca G.C., Salowe S.P., Bush B.L., RA Hermes J.D., Esser C.K., Hagmann W.K., Springer J.P., Johnson B.A.; RT "The NMR structure of the inhibited catalytic domain of human stromelysin- RT 1."; RL Nat. Struct. Biol. 1:111-118(1994). RN [19] RP STRUCTURE BY NMR OF 100-267. RX PubMed=9827994; DOI=10.1002/pro.5560071105; RA Stockman B.J., Waldon D.J., Gates J.A., Scahill T.A., Kloosterman D.A., RA Mizsak S.A., Jacobsen E.J., Belonga K.L., Mitchell M.A., Mao B., RA Petke J.D., Goodman L., Powers E.A., Ledbetter S.R., Kaytes P.S., RA Vogeli G., Marshall V.P., Petzold G.L., Poorman R.A.; RT "Solution structures of stromelysin complexed to thiadiazole inhibitors."; RL Protein Sci. 7:2281-2286(1998). RN [20] RP X-RAY CRYSTALLOGRAPHY. RX PubMed=8535233; DOI=10.1002/pro.5560041002; RA Becker J.W., Marcy A.I., Rokosz L.L., Axel M.G., Burbaum J.J., RA Fitzgerald P.M.D., Cameron P.M., Esser C.K., Hagmann W.K., Hermes J.D., RA Springer J.P.; RT "Stromelysin-1: three-dimensional structure of the inhibited catalytic RT domain and of the C-truncated proenzyme."; RL Protein Sci. 4:1966-1976(1995). RN [21] RP X-RAY CRYSTALLOGRAPHY. RX PubMed=8740360; DOI=10.1016/s0969-2126(96)00043-3; RA Dhanaraj V., Ye Q.-Z., Johnson L.L., Hupe D.J., Otwine D.F., RA Dunbar J.B. Jr., Rubin J.R., Pavlovsky A., Humblet C., Blundell T.L.; RT "X-ray structure of a hydroxamate inhibitor complex of stromelysin RT catalytic domain and its comparison with members of the zinc RT metalloproteinase superfamily."; RL Structure 4:375-386(1996). RN [22] RP X-RAY CRYSTALLOGRAPHY. RX PubMed=9083493; DOI=10.1021/jm960465t; RA Esser C.K., Bugianesi R.L., Caldwell C.G., Chapman K.T., Durette P.L., RA Girotra N.N., Kopka I.E., Lanza T.J., Levorse D.A., Maccoss M., Owens K.A., RA Ponpipom M.M., Simeone J.P., Harrison R.K., Niedzwiecki L., Becker J.W., RA Marcy A.I., Axel M.G., Christen A.J., McDonnell J., Moore V.L., RA Olszewski J.M., Saphos C., Visco D.M., Shen F., Colletti A., Kriter P.A., RA Hagmann W.K.; RT "Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl RT dipeptides."; RL J. Med. Chem. 40:1026-1040(1997). RN [23] RP X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH TIMP1. RX PubMed=9288970; DOI=10.1038/37995; RA Gomis-Rueth F.-X., Maskos K., Betz M., Bergner A., Huber R., Suzuki K., RA Yoshida N., Nagase H., Brew K., Bourenkov G.P., Bartunik H., Bode W.; RT "Mechanism of inhibition of the human matrix metalloproteinase stromelysin- RT 1 by TIMP-1."; RL Nature 389:77-81(1997). RN [24] RP X-RAY CRYSTALLOGRAPHY. RX PubMed=9792098; DOI=10.1002/pro.5560071008; RA Finzel B.C., Baldwin E.T., Bryant G.L. Jr., Hess G.F., Wilks J.W., RA Trepod C.M., Mott J.E., Marshall V.P., Petzold G.L., Poorman R.A., RA O'Sullivan T.J., Schostarez H.J., Mitchell M.A.; RT "Structural characterizations of nonpeptidic thiadiazole inhibitors of RT matrix metalloproteinases reveal the basis for stromelysin selectivity."; RL Protein Sci. 7:2118-2126(1998). RN [25] RP X-RAY CRYSTALLOGRAPHY. RX PubMed=10543949; DOI=10.1006/jmbi.1999.3147; RA Chen L., Rydel T.J., Gu F., Dunaway C.M., Pikul S., Dunham K.M., RA Barnett B.L.; RT "Crystal structure of the stromelysin catalytic domain at 2.0-A resolution: RT inhibitor-induced conformational changes."; RL J. Mol. Biol. 293:545-557(1999). RN [26] RP X-RAY CRYSTALLOGRAPHY. RX PubMed=10422833; DOI=10.1110/ps.8.7.1455; RA Pavlovsky A.G., Williams M.G., Ye Q.-Z., Ortwine D.F., Purchase C.F. II, RA White A.D., Dhanaraj V., Roth B.D., Johnson L.L., Hupe D., Humblet C., RA Blundell T.L.; RT "X-ray structure of human stromelysin catalytic domain complexed with RT nonpeptide inhibitors: implications for inhibitor selectivity."; RL Protein Sci. 8:1455-1462(1999). RN [27] RP STRUCTURE BY NMR OF 100-272. RX PubMed=9760240; DOI=10.1021/bi981328w; RA Li Y.C., Zhang X., Melton R., Ganu V., Gonnella N.C.; RT "Solution structure of the catalytic domain of human stromelysin-1 RT complexed to a potent, nonpeptidic inhibitor."; RL Biochemistry 37:14048-14056(1998). CC -!- FUNCTION: Metalloproteinase with a rather broad substrate specificity CC that can degrade fibronectin, laminin, gelatins of type I, III, IV, and CC V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates CC different molecules including growth factors, plasminogen or other CC matrix metalloproteinases such as MMP9 (PubMed:11029580, CC PubMed:1371271). Once released into the extracellular matrix (ECM), the CC inactive pro-enzyme is activated by the plasmin cascade signaling CC pathway (PubMed:2383557). Also acts intracellularly (PubMed:22265821). CC For example, in dopaminergic neurons, gets activated by the serine CC protease HTRA2 upon stress and plays a pivotal role in DA neuronal CC degeneration by mediating microglial activation and alpha- CC synuclein/SNCA cleavage (PubMed:21330369). In addition, plays a role in CC immune response and possesses antiviral activity against various CC viruses such as vesicular stomatitis virus, influenza A virus (H1N1) CC and human herpes virus 1 (PubMed:35940311). Mechanistically, CC translocates from the cytoplasm into the cell nucleus upon virus CC infection to influence NF-kappa-B activities (PubMed:35940311). CC {ECO:0000269|PubMed:11029580, ECO:0000269|PubMed:1371271, CC ECO:0000269|PubMed:21330369, ECO:0000269|PubMed:22265821, CC ECO:0000269|PubMed:2383557, ECO:0000269|PubMed:35940311}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Preferential cleavage where P1', P2' and P3' are hydrophobic CC residues.; EC=3.4.24.17; Evidence={ECO:0000269|PubMed:1371271, CC ECO:0000269|PubMed:21330369}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Note=Binds 4 Ca(2+) ions per subunit.; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Note=Binds 2 Zn(2+) ions per subunit.; CC -!- ACTIVITY REGULATION: Enzymatic activity is activated by HTRA2 in CC dopaminergic cells upon mitochondrial stress. CC {ECO:0000269|PubMed:22265821}. CC -!- INTERACTION: CC P08254; P50222: MEOX2; NbExp=3; IntAct=EBI-6957351, EBI-748397; CC -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular CC matrix. Nucleus {ECO:0000269|PubMed:35940311}. Cytoplasm CC {ECO:0000269|PubMed:35940311}. CC -!- DOMAIN: The conserved cysteine present in the cysteine-switch motif CC binds the catalytic zinc ion, thus inhibiting the enzyme. The CC dissociation of the cysteine from the zinc ion upon the activation- CC peptide release activates the enzyme. CC -!- PTM: Directly cleaved by HTRA2 to produce active form. CC {ECO:0000269|PubMed:22265821}. CC -!- DISEASE: Coronary heart disease 6 (CHDS6) [MIM:614466]: A CC multifactorial disease characterized by an imbalance between myocardial CC functional requirements and the capacity of the coronary vessels to CC supply sufficient blood flow. Decreased capacity of the coronary CC vessels is often associated with thickening and loss of elasticity of CC the coronary arteries. {ECO:0000269|PubMed:12477941, CC ECO:0000269|PubMed:8662692}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. A CC polymorphism in the MMP3 promoter region is associated with the risk of CC coronary heart disease and myocardial infarction, due to lower MMP3 CC proteolytic activity and higher extracellular matrix deposition in CC atherosclerotic lesions. CC -!- SIMILARITY: Belongs to the peptidase M10A family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X05232; CAA28859.1; -; mRNA. DR EMBL; J03209; AAA36321.1; -; mRNA. DR EMBL; U78045; AAB36942.1; -; Genomic_DNA. DR EMBL; AK223283; BAD97003.1; -; mRNA. DR EMBL; AK223291; BAD97011.1; -; mRNA. DR EMBL; AK313310; BAG36115.1; -; mRNA. DR EMBL; AF405705; AAK95247.1; -; Genomic_DNA. DR EMBL; CH471065; EAW67032.1; -; Genomic_DNA. DR EMBL; BC069676; AAH69676.1; -; mRNA. DR EMBL; BC069716; AAH69716.1; -; mRNA. DR EMBL; BC074815; AAH74815.1; -; mRNA. DR EMBL; BC074869; AAH74869.1; -; mRNA. DR EMBL; BC105954; AAI05955.1; -; mRNA. DR EMBL; BC107490; AAI07491.1; -; mRNA. DR EMBL; BC107491; AAI07492.1; -; mRNA. DR CCDS; CCDS8323.1; -. DR PIR; A28156; KCHUS1. DR RefSeq; NP_002413.1; NM_002422.5. DR PDB; 1B3D; X-ray; 2.30 A; A/B=100-272. DR PDB; 1B8Y; X-ray; 2.00 A; A=100-266. DR PDB; 1BIW; X-ray; 2.50 A; A/B=100-272. DR PDB; 1BM6; NMR; -; A=100-272. DR PDB; 1BQO; X-ray; 2.30 A; A/B=100-272. DR PDB; 1C3I; X-ray; 1.83 A; A/B=100-272. DR PDB; 1C8T; X-ray; 2.60 A; A/B=103-269. DR PDB; 1CAQ; X-ray; 1.80 A; A=100-267. DR PDB; 1CIZ; X-ray; 1.64 A; A=100-267. DR PDB; 1CQR; X-ray; 2.00 A; A/B=100-272. DR PDB; 1D5J; X-ray; 2.60 A; A/B=100-272. DR PDB; 1D7X; X-ray; 2.00 A; A/B=100-272. DR PDB; 1D8F; X-ray; 2.40 A; A/B=100-272. DR PDB; 1D8M; X-ray; 2.44 A; A/B=100-272. DR PDB; 1G05; X-ray; 2.45 A; A/B=100-272. DR PDB; 1G49; X-ray; 1.90 A; A/B=100-272. DR PDB; 1G4K; X-ray; 2.00 A; A/B/C=100-267. DR PDB; 1HFS; X-ray; 1.70 A; A=105-264. DR PDB; 1HY7; X-ray; 1.50 A; A/B=100-272. DR PDB; 1OO9; NMR; -; A=100-267. DR PDB; 1QIA; X-ray; 2.00 A; A/B/C/D=106-267. DR PDB; 1QIC; X-ray; 2.00 A; A/B/C/D=106-266. DR PDB; 1SLM; X-ray; 1.90 A; A=18-272. DR PDB; 1SLN; X-ray; 2.27 A; A=100-272. DR PDB; 1UEA; X-ray; 2.80 A; A/C=100-272. DR PDB; 1UMS; NMR; -; A=100-273. DR PDB; 1UMT; NMR; -; A=100-273. DR PDB; 1USN; X-ray; 1.80 A; A=100-264. DR PDB; 2D1O; X-ray; 2.02 A; A/B=100-270. DR PDB; 2JNP; NMR; -; A=105-265. DR PDB; 2JT5; NMR; -; A=105-265. DR PDB; 2JT6; NMR; -; A=105-265. DR PDB; 2SRT; NMR; -; A=100-272. DR PDB; 2USN; X-ray; 2.20 A; A=100-264. DR PDB; 3OHL; X-ray; 2.36 A; A=100-266. DR PDB; 3OHO; X-ray; 2.50 A; A=100-268. DR PDB; 3USN; NMR; -; A=100-267. DR PDB; 4DPE; X-ray; 1.96 A; A/B=100-272. DR PDB; 4G9L; X-ray; 1.88 A; A/B=100-272. DR PDB; 4JA1; X-ray; 1.96 A; A/B=100-272. DR PDB; 6MAV; X-ray; 2.37 A; A=100-267. DR PDB; 6N9D; X-ray; 2.67 A; A=100-264. DR PDB; 7S7L; X-ray; 2.34 A; A=100-272. DR PDB; 7S7M; X-ray; 3.00 A; A=100-272. DR AlphaFoldDB; P08254; -. DR BMRB; P08254; -. DR MDposit; P08254; -. DR MDRepo; P08254; -. DR SMR; P08254; -. DR BioGRID; 110458; 26. DR FunCoup; P08254; 213. DR IntAct; P08254; 23. DR NDEx; IQUERY-CP-MMP3; 12 NDEx IQuery Curated Pathways. DR STRING; 9606.ENSP00000299855; -. DR BindingDB; P08254; -. DR ChEMBL; CHEMBL283; -. DR DrugBank; DB02367; (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine. DR DrugBank; DB07145; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE. DR DrugBank; DB04140; 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide. DR DrugBank; DB08643; 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER. DR DrugBank; DB07390; 2-[3-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-ureido]-N-methyl-3-phenyl-propionamide. DR DrugBank; DB07988; 2-[3-(5-Mercapto-[1,3,4]thiadiazol-2yl)-ureido]-N-methyl-3-pentafluorophenyl-propionamide. DR DrugBank; DB02449; 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid. DR DrugBank; DB08030; 3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide. DR DrugBank; DB01996; 3-Methylpyridine. DR DrugBank; DB03033; 4-methoxybenzenesulfinate. DR DrugBank; DB03368; 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione. DR DrugBank; DB07987; [2-(5-Mercapto-[1,3,4]thiadiazol-2-ylcarbamoyl)-1-phenyl-ethyl]-carbamic acid benzyl ester. DR DrugBank; DB07986; [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID. DR DrugBank; DB02090; A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor. DR DrugBank; DB03880; Batimastat. DR DrugBank; DB07556; CGS-27023. DR DrugBank; DB08490; CTS-1027. DR DrugBank; DB02697; Hydroxyaminovaline. DR DrugBank; DB02255; Ilomastat. DR DrugBank; DB00786; Marimastat. DR DrugBank; DB07926; N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE. DR DrugBank; DB08507; N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID. DR DrugBank; DB01877; N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide. DR DrugBank; DB04232; N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide. DR DrugBank; DB02350; N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide. DR DrugBank; DB08271; N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID. DR DrugBank; DB08029; N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide. DR DrugBank; DB05495; PG-530742. DR DrugBank; DB04416; R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid. DR DrugCentral; P08254; -. DR GuidetoPHARMACOLOGY; 1630; -. DR MEROPS; M10.005; -. DR MoonProt; P08254; -. DR GlyCosmos; P08254; 2 sites, 1 glycan. DR GlyGen; P08254; 2 sites, 1 O-linked glycan (2 sites). DR iPTMnet; P08254; -. DR PhosphoSitePlus; P08254; -. DR BioMuta; MMP3; -. DR DMDM; 116857; -. DR jPOST; P08254; -. DR MassIVE; P08254; -. DR PaxDb; 9606-ENSP00000299855; -. DR PeptideAtlas; P08254; -. DR ProteomicsDB; 52102; -. DR ABCD; P08254; 1 sequenced antibody. DR Antibodypedia; 1509; 1536 antibodies from 53 providers. DR DNASU; 4314; -. DR Ensembl; ENST00000299855.10; ENSP00000299855.5; ENSG00000149968.12. DR GeneID; 4314; -. DR KEGG; hsa:4314; -. DR MANE-Select; ENST00000299855.10; ENSP00000299855.5; NM_002422.5; NP_002413.1. DR UCSC; uc001phj.2; human. DR AGR; HGNC:7173; -. DR ClinPGx; PA30886; -. DR CTD; 4314; -. DR DisGeNET; 4314; -. DR GeneCards; MMP3; -. DR HGNC; HGNC:7173; MMP3. DR HPA; ENSG00000149968; Tissue enhanced (adipose tissue, salivary gland, skin). DR MalaCards; MMP3; -. DR MIM; 185250; gene. DR MIM; 614466; phenotype. DR OpenTargets; ENSG00000149968; -. DR VEuPathDB; HostDB:ENSG00000149968; -. DR eggNOG; KOG1565; Eukaryota. DR GeneTree; ENSGT00940000159759; -. DR HOGENOM; CLU_015489_6_0_1; -. DR InParanoid; P08254; -. DR OMA; AACEVTS; -. DR OrthoDB; 406838at2759; -. DR PAN-GO; P08254; 3 GO annotations based on evolutionary models. DR PhylomeDB; P08254; -. DR BRENDA; 3.4.24.17; 2681. DR PathwayCommons; P08254; -. DR Reactome; R-HSA-1442490; Collagen degradation. DR Reactome; R-HSA-1474228; Degradation of the extracellular matrix. DR Reactome; R-HSA-1592389; Activation of Matrix Metalloproteinases. DR Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR SignaLink; P08254; -. DR SIGNOR; P08254; -. DR Agora; ENSG00000149968; -. DR BioGRID-ORCS; 4314; 13 hits in 1160 CRISPR screens. DR ChiTaRS; MMP3; human. DR EvolutionaryTrace; P08254; -. DR GeneWiki; MMP3; -. DR GenomeRNAi; 4314; -. DR Pharos; P08254; Tchem. DR PRO; PR:P08254; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; P08254; protein. DR Bgee; ENSG00000149968; Expressed in calcaneal tendon and 120 other cell types or tissues. DR ExpressionAtlas; P08254; baseline and differential. DR GO; GO:0005737; C:cytoplasm; EXP:UniProtKB. DR GO; GO:0005829; C:cytosol; IEA:Ensembl. DR GO; GO:0031012; C:extracellular matrix; IEA:InterPro. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; EXP:UniProtKB. DR GO; GO:0004175; F:endopeptidase activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0004222; F:metalloendopeptidase activity; EXP:UniProtKB. DR GO; GO:0008237; F:metallopeptidase activity; IDA:UniProtKB. DR GO; GO:0008233; F:peptidase activity; IDA:UniProtKB. DR GO; GO:0004252; F:serine-type endopeptidase activity; TAS:Reactome. DR GO; GO:0008270; F:zinc ion binding; IEA:InterPro. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; TAS:ARUK-UCL. DR GO; GO:0071732; P:cellular response to nitric oxide; TAS:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; ISS:ParkinsonsUK-UCL. DR GO; GO:0071492; P:cellular response to UV-A; IDA:UniProtKB. DR GO; GO:0030574; P:collagen catabolic process; IBA:GO_Central. DR GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome. DR GO; GO:0030198; P:extracellular matrix organization; IBA:GO_Central. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IDA:ParkinsonsUK-UCL. DR GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IDA:ParkinsonsUK-UCL. DR GO; GO:0030163; P:protein catabolic process; IEA:Ensembl. DR GO; GO:0006508; P:proteolysis; IDA:UniProtKB. DR GO; GO:0150077; P:regulation of neuroinflammatory response; TAS:ARUK-UCL. DR GO; GO:1904645; P:response to amyloid-beta; TAS:ARUK-UCL. DR CDD; cd00094; HX; 1. DR CDD; cd04278; ZnMc_MMP; 1. DR FunFam; 3.40.390.10:FF:000007; Collagenase 3; 1. DR FunFam; 2.110.10.10:FF:000002; Matrix metallopeptidase 3; 1. DR Gene3D; 3.40.390.10; Collagenase (Catalytic Domain); 1. DR Gene3D; 2.110.10.10; Hemopexin-like domain; 1. DR InterPro; IPR000585; Hemopexin-like_dom. DR InterPro; IPR036375; Hemopexin-like_dom_sf. DR InterPro; IPR018487; Hemopexin-like_repeat. DR InterPro; IPR018486; Hemopexin_CS. DR InterPro; IPR033739; M10A_MMP. DR InterPro; IPR024079; MetalloPept_cat_dom_sf. DR InterPro; IPR001818; Pept_M10_metallopeptidase. DR InterPro; IPR021190; Pept_M10A. DR InterPro; IPR021158; Pept_M10A_Zn_BS. DR InterPro; IPR006026; Peptidase_Metallo. DR InterPro; IPR002477; Peptidoglycan-bd-like. DR InterPro; IPR036365; PGBD-like_sf. DR PANTHER; PTHR10201; MATRIX METALLOPROTEINASE; 1. DR PANTHER; PTHR10201:SF215; STROMELYSIN-1; 1. DR Pfam; PF00045; Hemopexin; 4. DR Pfam; PF00413; Peptidase_M10; 1. DR Pfam; PF01471; PG_binding_1; 1. DR PIRSF; PIRSF001191; Peptidase_M10A_matrix; 1. DR PRINTS; PR00138; MATRIXIN. DR SMART; SM00120; HX; 4. DR SMART; SM00235; ZnMc; 1. DR SUPFAM; SSF50923; Hemopexin-like domain; 1. DR SUPFAM; SSF55486; Metalloproteases ('zincins'), catalytic domain; 1. DR SUPFAM; SSF47090; PGBD-like; 1. DR PROSITE; PS00546; CYSTEINE_SWITCH; 1. DR PROSITE; PS00024; HEMOPEXIN; 1. DR PROSITE; PS51642; HEMOPEXIN_2; 4. DR PROSITE; PS00142; ZINC_PROTEASE; 1. PE 1: Evidence at protein level; KW 3D-structure; Calcium; Collagen degradation; Cytoplasm; KW Direct protein sequencing; Disulfide bond; Extracellular matrix; Hydrolase; KW Immunity; Innate immunity; Metal-binding; Metalloprotease; Nucleus; KW Protease; Proteomics identification; Reference proteome; Repeat; Secreted; KW Signal; Zinc; Zymogen. FT SIGNAL 1..17 FT /evidence="ECO:0000305|PubMed:3360803" FT PROPEP 18..99 FT /note="Activation peptide" FT /id="PRO_0000028728" FT CHAIN 100..477 FT /note="Stromelysin-1" FT /id="PRO_0000028729" FT REPEAT 287..336 FT /note="Hemopexin 1" FT REPEAT 337..383 FT /note="Hemopexin 2" FT REPEAT 385..433 FT /note="Hemopexin 3" FT REPEAT 434..477 FT /note="Hemopexin 4" FT REGION 262..287 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 90..97 FT /note="Cysteine switch" FT /evidence="ECO:0000250" FT COMPBIAS 276..285 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 219 FT BINDING 92 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /ligand_note="catalytic" FT /note="in inhibited form" FT BINDING 124 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT BINDING 158 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT BINDING 168 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 170 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 175 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT BINDING 176 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT BINDING 178 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT BINDING 180 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT BINDING 183 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 190 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT BINDING 192 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT BINDING 194 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT BINDING 196 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 198 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT BINDING 199 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT BINDING 201 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT BINDING 201 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT BINDING 218 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:8740360" FT BINDING 222 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:8740360" FT BINDING 228 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:8740360" FT BINDING 297 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250" FT BINDING 389 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250" FT BINDING 438 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250" FT DISULFID 290..477 FT /evidence="ECO:0000250" FT VARIANT 45 FT /note="K -> E (in dbSNP:rs679620)" FT /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.6, FT ECO:0000269|Ref.7" FT /id="VAR_013090" FT CONFLICT 420 FT /note="P -> L (in Ref. 3)" FT /evidence="ECO:0000305" FT HELIX 34..41 FT /evidence="ECO:0007829|PDB:1SLM" FT HELIX 58..70 FT /evidence="ECO:0007829|PDB:1SLM" FT HELIX 81..86 FT /evidence="ECO:0007829|PDB:1SLM" FT STRAND 96..98 FT /evidence="ECO:0007829|PDB:1SLM" FT STRAND 102..104 FT /evidence="ECO:0007829|PDB:7S7L" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 123..125 FT /evidence="ECO:0007829|PDB:1CAQ" FT HELIX 127..142 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 144..146 FT /evidence="ECO:0007829|PDB:2SRT" FT STRAND 148..151 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 153..155 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 158..164 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 169..171 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 176..179 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:1HY7" FT TURN 190..193 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 195..198 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2SRT" FT STRAND 203..211 FT /evidence="ECO:0007829|PDB:1HY7" FT HELIX 212..224 FT /evidence="ECO:0007829|PDB:1HY7" FT STRAND 232..234 FT /evidence="ECO:0007829|PDB:4JA1" FT STRAND 237..239 FT /evidence="ECO:0007829|PDB:1SLM" FT HELIX 240..243 FT /evidence="ECO:0007829|PDB:1USN" FT HELIX 246..248 FT /evidence="ECO:0007829|PDB:1CIZ" FT HELIX 253..263 FT /evidence="ECO:0007829|PDB:1HY7" SQ SEQUENCE 477 AA; 53977 MW; 96194833B907668D CRC64; MKSLPILLLL CVAVCSAYPL DGAARGEDTS MNLVQKYLEN YYDLKKDVKQ FVRRKDSGPV VKKIREMQKF LGLEVTGKLD SDTLEVMRKP RCGVPDVGHF RTFPGIPKWR KTHLTYRIVN YTPDLPKDAV DSAVEKALKV WEEVTPLTFS RLYEGEADIM ISFAVREHGD FYPFDGPGNV LAHAYAPGPG INGDAHFDDD EQWTKDTTGT NLFLVAAHEI GHSLGLFHSA NTEALMYPLY HSLTDLTRFR LSQDDINGIQ SLYGPPPDSP ETPLVPTEPV PPEPGTPANC DPALSFDAVS TLRGEILIFK DRHFWRKSLR KLEPELHLIS SFWPSLPSGV DAAYEVTSKD LVFIFKGNQF WAIRGNEVRA GYPRGIHTLG FPPTVRKIDA AISDKEKNKT YFFVEDKYWR FDEKRNSMEP GFPKQIAEDF PGIDSKIDAV FEEFGFFYFF TGSSQLEFDP NAKKVTHTLK SNSWLNC //